Amendment history : Corrigendum ( April 2018 ) Expression of Concern ( November 2017 ) iNKT cells require TSC 1 for terminal maturation and effector lineage fate decisions

Jinhong Wu,Jialong Yang,Kai Yang,Hongxia Wang,Balachandra Gorentla,Jinwook Shin,Yurong Qiu,Loretta G. Que,W. Michael Foster,Zhenwei Xia,Hongbo Chi,Xiao-Ping Zhong
2018-01-01
Abstract:Terminal maturation of invariant NKT (iNKT) cells from stage 2 (CD44+NK1.1–) to stage 3 (CD44+NK1.1+) is accompanied by a functional acquisition of a predominant IFN-g– producing (iNKT-1) phenotype; however, some cells develop into IL-17–producing iNKT (iNKT-17) cells. iNKT-17 cells are rare and restricted to a CD44+NK1.1– lineage. It is unclear how iNKT terminal maturation is regulated and what factors mediate the predominance of iNKT-1 compared with iNKT-17. The tumor suppressor tuberous sclerosis 1 (TSC1) is an important negative regulator of mTOR signaling, which regulates T cell differentiation, function, and trafficking. Here, we determined that mice lacking TSC1 exhibit a developmental block of iNKT differentiation at stage 2 and skew from a predominantly iNKT-1 population toward a predominantly iNKT-17 population, leading to enhanced airway hypersensitivity. Evaluation of purified iNKT cells revealed that TSC1 promotes T-bet, which regulates iNKT maturation, but downregulates ICOS expression in iNKT cells by inhibiting mTOR complex 1 (mTORC1). Furthermore, mice lacking T-bet exhibited both a terminal maturation defect [...] Research Article Immunology
What problem does this paper attempt to address?